Tejas Dharmaraj

Mr. Tejas Dharmaraj


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2023 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
TDTejas Dharmaraj
Tejas Dharmaraj
MKMichael J Kratochvil
Michael J Kratochvil
JPJulie D Pourtois
Julie D Pourtois
QCQingquan Chen
Qingquan Chen
MHMaryam Hajfathalian
Maryam Hajfathalian
PBPaul Bollyky
Paul Bollyky
Extensive efforts are underway to develop bacteriophages as therapies against antibiotic-resistant bacteria. However, these efforts are confounded by the instability of phage preparations and a lack of suitable tools to assess active phage concentrations over time. In this study, we use dynamic light scattering (DLS) to measure changes in phage physical state in response to environmental factors and time, finding that phages tend to decay and form aggregates and that the degree of aggregation can be used to predict phage bioactivity. We then use DLS to optimize phage storage conditions for phages from human clinical trials, predict bioactivity in 50-y-old archival stocks, and evaluate phage samples for use in a phage therapy/wound infection model. We also provide a web application (Phage-Estimator of Lytic Function) to facilitate DLS studies of phages. We conclude that DLS provides a rapid, convenient, and nondestructive tool for quality control of phage preparations in academic and commercial settings.

15 June 2017 in Frontiers in Genetics
Verified
Journal Article
Open access
AFAlyssa Florwick
Alyssa Florwick
TDTejas Dharmaraj
Tejas Dharmaraj
JJJulie Jurgens
Julie Jurgens
DVDavid Valle
David Valle
KWKatherine L. Wilson
Katherine L. Wilson
Mutations in LMNA, encoding nuclear intermediate filament proteins lamins A and C, cause multiple diseases (‘laminopathies’) including muscular dystrophy, dilated cardiomyopathy, familial partial lipodystrophy (FPLD2), insulin resistance syndrome and progeria. To assess the prevalence of LMNA missense mutations (‘variants’) in a broad, ethnically-diverse population, we compared missense alleles found among 60,706 unrelated individuals in the ExAC cohort to those identified in 1,404 individuals in the laminopathy database (UMD-LMNA). We identified 169 variants in the ExAC cohort, of which 37 (~22%) are disease-associated including p.I299V (allele frequency 0.0402%), p.G602S (allele frequency 0.0262%) and p.R644C (allele frequency 0.124%), suggesting certain LMNA mutations are more common than previously recognized. Independent analysis of LMNA variants via the type 2 diabetes (T2D) Knowledge Portal showed that variant p.G602S associated significantly with type 2 diabetes (p=0.02; odds ratio=4.58), and was more frequent in African Americans (allele frequency 0.297%). The FPLD2-associated variant I299V was most prevalent in Latinos (allele frequency 0.347%). The ExAC cohort also revealed 132 novel LMNA missense variants including p.K108E (limited to individuals with psychiatric disease; predicted to perturb coil-1B), p.R397C and p.R427C (predicted to perturb filament biogenesis), p.G638R and p.N660D (predicted to perturb prelamin A processing), and numerous Ig-fold variants predicted to perturb phenotypically-characteristic protein-protein interactions. Overall, this two-pronged strategy— mining a large database for missense variants in a single gene (LMNA), coupled to knowledge about the structure, biogenesis and functions of A-type lamins— revealed an unexpected number of LMNA variants, including novel variants predicted to perturb lamin assembly or function. Interestingly, this study also correlated novel variant K108E with psychiatric disease, identified known variant p.I299V as a potential risk factor for metabolic disease in Latinos, linked variant p.G602 with type 2 diabetes, and specifically identified p.G602S as a predictor of diabetes risk in African Americans.

17 May 2018 in Cells
Verified
Journal Article
Open access
PDF file
DSDan Simon
Dan Simon
AWAmanda Wriston
Amanda Wriston
QFQiong Fan
Qiong Fan
JSJeffrey Shabanowitz
Jeffrey Shabanowitz
AFAlyssa Florwick
Alyssa Florwick
KWKatherine L. Wilson
Katherine L. Wilson
The LMNA gene encodes lamins A and C with key roles in nuclear structure, signaling, gene regulation, and genome integrity. Mutations in LMNA cause over 12 diseases (‘laminopathies’). Lamins A and C are identical for their first 566 residues. However, they form separate filaments in vivo, with apparently distinct roles. We report that lamin A is β-O-linked N-acetylglucosamine-(O-GlcNAc)-modified in human hepatoma (Huh7) cells and in mouse liver. In vitro assays with purified O-GlcNAc transferase (OGT) enzyme showed robust O-GlcNAcylation of recombinant mature lamin A tails (residues 385–646), with no detectable modification of lamin B1, lamin C, or ‘progerin’ (Δ50) tails. Using mass spectrometry, we identified 11 O-GlcNAc sites in a ‘sweet spot’ unique to lamin A, with up to seven sugars per peptide. Most sites were unpredicted by current algorithms. Double-mutant (S612A/T643A) lamin A tails were still robustly O-GlcNAc-modified at seven sites. By contrast, O-GlcNAcylation was undetectable on tails bearing deletion Δ50, which causes Hutchinson–Gilford progeria syndrome, and greatly reduced by deletion Δ35. We conclude that residues deleted in progeria are required for substrate recognition and/or modification by OGT in vitro. Interestingly, deletion Δ35, which does not remove the majority of identified O-GlcNAc sites, does remove potential OGT-association motifs (lamin A residues 622–625 and 639–645) homologous to that in mouse Tet1. These biochemical results are significant because they identify a novel molecular pathway that may profoundly influence lamin A function. The hypothesis that lamin A is selectively regulated by OGT warrants future testing in vivo, along with two predictions: genetic variants may contribute to disease by perturbing OGT-dependent regulation, and nutrient or other stresses might cause OGT to misregulate wildtype lamin A.

7 January 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
AEArne Echterhof
Arne Echterhof
TDTejas Dharmaraj
Tejas Dharmaraj
PBPatrick M. Blankenberg
Patrick M. Blankenberg
BTBobby Targ
Bobby Targ
TNThomas D. Nguyen
Thomas D. Nguyen
FBFrancis G. Blankenberg
Francis G. Blankenberg
Bacteriophage (phage) therapy holds great promise for treating antimicrobial-resistant infections. However, the pharmacokinetics (PK) of phage have been difficult to characterize due to a lack of standardized protocols for phage purification, labeling, and in vivo quantification. Here, we present robust methods for ultrapure phage preparation, as well as non-destructive, highly stable attachment of radio-iodide to phage using a well-described Sulfo-SHPP linker. We purified and radiolabeled the phage strains, PAML-31-1, OMKO1, and Luz24, lytic to drug-resistant Pseudomonas aeruginosa, for biodistribution assay in normal young adult CD-1 mice injected via intravenous injection. Groups of five mice were euthanized, and tissues/organs were removed for weighing and scintillation well counting of 125 I activity. A physiologically based PK model was then constructed, focusing on compartments describing blood, lung, muscle, bone, liver, stomach, spleen, small intestines, large intestines, and kidney. Tissue partition coefficients (K P ) were estimated for high-perfusion organs (lung and kidney) as 0.000138, GI organs (liver, spleen, and stomach) as 0.627, and all other organs as 0.220. Monte Carlo simulations predicted rapid elimination of phage in humans, with blood concentrations being <10 2 PFU/mL by 12 h, whereas simulated multi-dose regimens and continuous infusion regimens were predicted to have sustained concentrations. Our physiologically based PK model of phage represents the first rigorous preclinical assessment of phage PK utilizing contemporary pharmacometric approaches amenable to both preclinical and clinical study design.

29 November 2017 in Nature
Verified
Journal Article
Closed access
TDTejas Dharmaraj
Tejas Dharmaraj
KWKatherine L. Wilson
Katherine L. Wilson

26 October 2017 in bioRxiv
Verified
Preprint
Open access
PDF file
DSDan N. Simon
Dan N. Simon
AWAmanda Wriston
Amanda Wriston
QFQiong Fan
Qiong Fan
JSJeffrey Shabanowitz
Jeffrey Shabanowitz
AFAlyssa Florwick
Alyssa Florwick
KWKatherine L. Wilson
Katherine L. Wilson
The LMNA gene encodes lamins A and C with key roles in nuclear structure, signaling, chromatin organization, and genome integrity. Mutations in LMNA cause >12 diseases, termed laminopathies. Lamins A and C are identical for their first 566 residues. However, they form distinct filaments in vivo with apparently distinct roles. We report that lamin A is O -GlcNAc modified in human hepatoma (Huh7) cells and in mouse liver. In vitro assays with purified OGT enzyme showed robust O -GlcNAcylation of recombinant mature lamin A tails (residues 385-646), with no detectable modification of lamin B1, lamin C, or ‘progerin’ (Δ50) tails. Using mass spectrometry, we identified 11 O -GlcNAc sites in a ‘sweet spot’ unique to lamin A, with up to seven sugars per peptide. Most sites were unpredicted by current algorithms. Double-mutant (S612A/T643A) lamin A tails were still robustly O -GlcNAc-modified at seven sites. By contrast, O -GlcNAcylation was undetectable on tails bearing deletion Δ50, which causes Hutchinson-Gilford progeria syndrome, and greatly reduced by deletion Δ35, suggesting this region is required for substrate recognition or modification by OGT in vitro. These results suggest OGT, an essential protein and master regulator, regulates partners or function(s) unique to lamin A that are lost in progeria.